605 related articles for article (PubMed ID: 26235907)
1. Use of botulinum toxin for genitourinary conditions: What is the evidence?
da Silva CM; Chancellor MB; Smith CP; Cruz F
Toxicon; 2015 Dec; 107(Pt A):141-7. PubMed ID: 26235907
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.
Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J
J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.
Kennelly M; Dmochowski R; Schulte-Baukloh H; Ethans K; Del Popolo G; Moore C; Jenkins B; Guard S; Zheng Y; Karsenty G;
Neurourol Urodyn; 2017 Feb; 36(2):368-375. PubMed ID: 26607743
[TBL] [Abstract][Full Text] [Related]
5. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F; Nitti V
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin treatment for bladder dysfunction.
Santos-Silva A; da Silva CM; Cruz F
Int J Urol; 2013 Oct; 20(10):956-62. PubMed ID: 23634720
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
[TBL] [Abstract][Full Text] [Related]
8. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
9. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
10. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
Nitti V; Haag-Molkenteller C; Kennelly M; Chancellor M; Jenkins B; Schurch B
Medicine (Baltimore); 2023 Jul; 102(S1):e32377. PubMed ID: 37499088
[TBL] [Abstract][Full Text] [Related]
11. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
[TBL] [Abstract][Full Text] [Related]
12. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin-what urologic uses does the data support?
Seth J; Khan MS; Dasgupta P; Sahai A
Curr Urol Rep; 2013 Jun; 14(3):227-34. PubMed ID: 23625366
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
15. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
16. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Nambiar A; Lucas M
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Cheng T; Shuang WB; Jia DD; Zhang M; Tong XN; Yang WD; Jia XM; Li S
PLoS One; 2016; 11(7):e0159307. PubMed ID: 27463810
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]